Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

Hippo Kinase Loss Contributes to Del(20q) Hematologic Malignancies through Chronic Innate Immune Activation.

Stoner SA, Yan M, Liu KTH, Arimoto KI, Shima T, Wang HY, Johnson DT, Bejar R, Jamieson C, Guan KL, Zhang DE.

Blood. 2019 Aug 21. pii: blood.2019000170. doi: 10.1182/blood.2019000170. [Epub ahead of print]

PMID:
31434702
2.

A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.

Bell JA, Galaznik A, Pompilus F, Strzok S, Bejar R, Scipione F, Fram RJ, Faller DV, Cano S, Marquis P.

J Patient Rep Outcomes. 2019 Jun 19;3(1):35. doi: 10.1186/s41687-019-0123-4.

3.

The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes.

Sekeres MA, Gore SD, Stablein DM, DiFronzo N, Abel GA, DeZern AE, Troy JD, Rollison DE, Thomas JW, Waclawiw MA, Liu JJ, Al Baghdadi T, Walter MJ, Bejar R, Gorak EJ, Starczynowski DT, Foran JM, Cerhan JR, Moscinski LC, Komrokji RS, Deeg HJ, Epling-Burnette PK.

Leuk Lymphoma. 2019 May 21:1-11. doi: 10.1080/10428194.2019.1616186. [Epub ahead of print]

PMID:
31111762
4.

Aging Human Hematopoietic Stem Cells Manifest Profound Epigenetic Reprogramming of Enhancers That May Predispose to Leukemia.

Adelman ER, Huang HT, Roisman A, Olsson A, Colaprico A, Qin T, Lindsley RC, Bejar R, Salomonis N, Grimes HL, Figueroa ME.

Cancer Discov. 2019 Aug;9(8):1080-1101. doi: 10.1158/2159-8290.CD-18-1474. Epub 2019 May 13.

PMID:
31085557
5.

Clonal Hematopoiesis in Aging.

Park SJ, Bejar R.

Curr Stem Cell Rep. 2018 Sep;4(3):209-219. doi: 10.1007/s40778-018-0133-9. Epub 2018 Jul 19.

6.

Myelodysplastic syndrome-associated spliceosome gene mutations enhance innate immune signaling.

Pollyea DA, Harris C, Rabe JL, Hedin BR, De Arras L, Katz S, Wheeler E, Bejar R, Walter MJ, Jordan CT, Pietras EM, Alper S.

Haematologica. 2019 Sep;104(9):e388-e392. doi: 10.3324/haematol.2018.214155. Epub 2019 Mar 7. No abstract available.

7.

MDS overlap disorders and diagnostic boundaries.

Tanaka TN, Bejar R.

Blood. 2019 Mar 7;133(10):1086-1095. doi: 10.1182/blood-2018-10-844670. Epub 2019 Jan 22. Review.

PMID:
30670443
8.

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.

Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, Walter MJ, List AF, Komrokji RS, Padron E, Sallman D, Papaemmanuil E, Campbell PJ, Savona MR, Seegmiller A, Adès L, Fenaux P, Shih LY, Bowen D, Groves MJ, Tauro S, Fontenay M, Kosmider O, Bar-Natan M, Steensma D, Stone R, Heuser M, Thol F, Cazzola M, Malcovati L, Karsan A, Ganster C, Hellström-Lindberg E, Boultwood J, Pellagatti A, Santini V, Quek L, Vyas P, Tüchler H, Greenberg PL, Bejar R; International Working Group for MDS Molecular Prognostic Committee.

Leukemia. 2019 Jul;33(7):1747-1758. doi: 10.1038/s41375-018-0351-2. Epub 2019 Jan 11.

9.

Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials.

Galanina N, Bejar R, Choi M, Goodman A, Wieduwilt M, Mulroney C, Kim L, Yeerna H, Tamayo P, Vergilio JA, Mughal TI, Miller V, Jamieson C, Kurzrock R.

Cancers (Basel). 2018 Dec 21;11(1). pii: E11. doi: 10.3390/cancers11010011.

10.

What biologic factors predict for transformation to AML?

Bejar R.

Best Pract Res Clin Haematol. 2018 Dec;31(4):341-345. doi: 10.1016/j.beha.2018.10.002. Epub 2018 Oct 23. Review.

PMID:
30466744
11.

Managing Clonal Hematopoiesis in Patients With Solid Tumors.

Bolton KL, Gillis NK, Coombs CC, Takahashi K, Zehir A, Bejar R, Garcia-Manero G, Futreal A, Jensen BC, Diaz LA Jr, Gupta D, Mantha S, Klimek V, Papaemmanuil E, Levine R, Padron E.

J Clin Oncol. 2019 Jan 1;37(1):7-11. doi: 10.1200/JCO.18.00331. Epub 2018 Nov 7. No abstract available.

PMID:
30403571
12.

JAK2 double minutes with resultant simultaneous amplification of JAK2 and CD274 in a therapy-related myelodysplastic syndrome evolving into an acute myeloid leukaemia.

Wang HY, Dell'Aquila ML, Dvanajscak Z, Bejar R, Broome HE, Hsi E, Murray SS, Thorson JA.

Br J Haematol. 2019 May;185(3):566-570. doi: 10.1111/bjh.15538. Epub 2018 Aug 21. No abstract available.

PMID:
30132795
13.

The Emerging Potential for Network Analysis to Inform Precision Cancer Medicine.

Ozturk K, Dow M, Carlin DE, Bejar R, Carter H.

J Mol Biol. 2018 Sep 14;430(18 Pt A):2875-2899. doi: 10.1016/j.jmb.2018.06.016. Epub 2018 Jun 15. Review.

14.

Germ line tissues for optimal detection of somatic variants in myelodysplastic syndromes.

Padron E, Ball MC, Teer JK, Painter JS, Yoder SJ, Zhang C, Zhang L, Moscinski LC, Rollison DE, Gore SD, Bejar R, Walter MJ, Sekeres MA, Komrokji RS, Epling-Burnette PK.

Blood. 2018 May 24;131(21):2402-2405. doi: 10.1182/blood-2018-01-827881. Epub 2018 Apr 16. No abstract available.

15.

SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes.

Sallman DA, Tanaka TN, List A, Bejar R.

Clin Lymphoma Myeloma Leuk. 2017 Oct;17(10):613-620. doi: 10.1016/j.clml.2017.09.018. Epub 2017 Sep 25. Review.

PMID:
29025689
16.

Molecular Data and the IPSS-R: How Mutational Burden Can Affect Prognostication in MDS.

Nazha A, Bejar R.

Curr Hematol Malig Rep. 2017 Oct;12(5):461-467. doi: 10.1007/s11899-017-0407-9. Review.

PMID:
28844082
17.

CHIP, ICUS, CCUS and other four-letter words.

Bejar R.

Leukemia. 2017 Sep;31(9):1869-1871. doi: 10.1038/leu.2017.181. Epub 2017 Jun 8. Review.

PMID:
28592887
18.

New Insight Into the Biology, Risk Stratification, and Targeted Treatment of Myelodysplastic Syndromes.

Haider M, Duncavage EJ, Afaneh KF, Bejar R, List AF.

Am Soc Clin Oncol Educ Book. 2017;37:480-494. doi: 10.14694/EDBK_175397.

PMID:
28561687
19.

Precancer Atlas to Drive Precision Prevention Trials.

Spira A, Yurgelun MB, Alexandrov L, Rao A, Bejar R, Polyak K, Giannakis M, Shilatifard A, Finn OJ, Dhodapkar M, Kay NE, Braggio E, Vilar E, Mazzilli SA, Rebbeck TR, Garber JE, Velculescu VE, Disis ML, Wallace DC, Lippman SM.

Cancer Res. 2017 Apr 1;77(7):1510-1541. doi: 10.1158/0008-5472.CAN-16-2346.

20.

The Impact of Somatic and Germline Mutations in Myelodysplastic Syndromes and Related Disorders.

Bejar R, Greenberg PL.

J Natl Compr Canc Netw. 2017 Jan;15(1):131-135. No abstract available.

PMID:
28040723
21.

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Greenberg PL, Stone RM, Al-Kali A, Barta SK, Bejar R, Bennett JM, Carraway H, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Horsfall R, Johnson RA, Juckett M, Klimek VM, Komrokji R, Kujawski LA, Maness LJ, O'Donnell MR, Pollyea DA, Shami PJ, Stein BL, Walker AR, Westervelt P, Zeidan A, Shead DA, Smith C.

J Natl Compr Canc Netw. 2017 Jan;15(1):60-87.

PMID:
28040720
22.

Implications of molecular genetic diversity in myelodysplastic syndromes.

Bejar R.

Curr Opin Hematol. 2017 Mar;24(2):73-78. doi: 10.1097/MOH.0000000000000313. Review.

23.

Computational drug treatment simulations on projections of dysregulated protein networks derived from the myelodysplastic mutanome match clinical response in patients.

Drusbosky L, Medina C, Martuscello R, Hawkins KE, Chang M, Lamba JK, Vali S, Kumar A, Singh NK, Abbasi T, Sekeres MA, Mallo M, Sole F, Bejar R, Cogle CR.

Leuk Res. 2017 Jan;52:1-7. doi: 10.1016/j.leukres.2016.11.004. Epub 2016 Nov 6.

24.

Leveraging premalignant biology for immune-based cancer prevention.

Spira A, Disis ML, Schiller JT, Vilar E, Rebbeck TR, Bejar R, Ideker T, Arts J, Yurgelun MB, Mesirov JP, Rao A, Garber J, Jaffee EM, Lippman SM.

Proc Natl Acad Sci U S A. 2016 Sep 27;113(39):10750-8. doi: 10.1073/pnas.1608077113. Epub 2016 Sep 16.

25.

Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.

Steensma DP, Abedi M, Bejar R, Cogle CR, Foucar K, Garcia-Manero G, George TI, Grinblatt D, Komrokji R, Ma X, Maciejewski J, Pollyea DA, Savona MR, Scott B, Sekeres MA, Thompson MA, Swern AS, Nifenecker M, Sugrue MM, Erba H.

BMC Cancer. 2016 Aug 19;16:652. doi: 10.1186/s12885-016-2710-6.

26.

Distinct splicing signatures affect converged pathways in myelodysplastic syndrome patients carrying mutations in different splicing regulators.

Qiu J, Zhou B, Thol F, Zhou Y, Chen L, Shao C, DeBoever C, Hou J, Li H, Chaturvedi A, Ganser A, Bejar R, Zhang DE, Fu XD, Heuser M.

RNA. 2016 Oct;22(10):1535-49. doi: 10.1261/rna.056101.116. Epub 2016 Aug 4.

27.

Splicing Factor Mutations in Cancer.

Bejar R.

Adv Exp Med Biol. 2016;907:215-28. doi: 10.1007/978-3-319-29073-7_9.

PMID:
27256388
28.

DMSO Increases Mutation Scanning Detection Sensitivity of High-Resolution Melting in Clinical Samples.

Song C, Castellanos-Rizaldos E, Bejar R, Ebert BL, Makrigiorgos GM.

Clin Chem. 2015 Nov;61(11):1354-62. doi: 10.1373/clinchem.2015.245357. Epub 2015 Oct 2.

29.

MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance.

Kwok B, Hall JM, Witte JS, Xu Y, Reddy P, Lin K, Flamholz R, Dabbas B, Yung A, Al-Hafidh J, Balmert E, Vaupel C, El Hader C, McGinniss MJ, Nahas SA, Kines J, Bejar R.

Blood. 2015 Nov 19;126(21):2355-61. doi: 10.1182/blood-2015-08-667063. Epub 2015 Oct 1.

30.

Myelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing?

Bejar R.

Curr Hematol Malig Rep. 2015 Sep;10(3):282-91. doi: 10.1007/s11899-015-0270-5. Review.

31.

Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.

Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP, Ebert BL.

Blood. 2015 Jul 2;126(1):9-16. doi: 10.1182/blood-2015-03-631747. Epub 2015 Apr 30.

32.

Myelodysplastic syndromes, version 2.2015.

Greenberg PL, Stone RM, Bejar R, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Klimek V, Komrokji R, Kujawski LA, Maness LJ, O'Donnell MR, Pollyea DA, Scott B, Shami PJ, Stein BL, Westervelt P, Wheeler B, Shead DA, Smith C; National comprehensive cancer network.

J Natl Compr Canc Netw. 2015 Mar;13(3):261-72.

33.

X-linked macrocytic dyserythropoietic anemia in females with an ALAS2 mutation.

Sankaran VG, Ulirsch JC, Tchaikovskii V, Ludwig LS, Wakabayashi A, Kadirvel S, Lindsley RC, Bejar R, Shi J, Lovitch SB, Bishop DF, Steensma DP.

J Clin Invest. 2015 Apr;125(4):1665-9. doi: 10.1172/JCI78619. Epub 2015 Feb 23.

34.

Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS.

Schneider RK, Ademà V, Heckl D, Järås M, Mallo M, Lord AM, Chu LP, McConkey ME, Kramann R, Mullally A, Bejar R, Solé F, Ebert BL.

Cancer Cell. 2014 Oct 13;26(4):509-20. doi: 10.1016/j.ccr.2014.08.001. Epub 2014 Sep 18.

35.

Recent developments in myelodysplastic syndromes.

Bejar R, Steensma DP.

Blood. 2014 Oct 30;124(18):2793-803. doi: 10.1182/blood-2014-04-522136. Epub 2014 Sep 18. Review.

36.

TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.

Bejar R, Lord A, Stevenson K, Bar-Natan M, Pérez-Ladaga A, Zaneveld J, Wang H, Caughey B, Stojanov P, Getz G, Garcia-Manero G, Kantarjian H, Chen R, Stone RM, Neuberg D, Steensma DP, Ebert BL.

Blood. 2014 Oct 23;124(17):2705-12. doi: 10.1182/blood-2014-06-582809. Epub 2014 Sep 15.

37.

Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation.

Bejar R, Stevenson KE, Caughey B, Lindsley RC, Mar BG, Stojanov P, Getz G, Steensma DP, Ritz J, Soiffer R, Antin JH, Alyea E, Armand P, Ho V, Koreth J, Neuberg D, Cutler CS, Ebert BL.

J Clin Oncol. 2014 Sep 1;32(25):2691-8. doi: 10.1200/JCO.2013.52.3381. Epub 2014 Aug 4.

38.

Clinical and genetic predictors of prognosis in myelodysplastic syndromes.

Bejar R.

Haematologica. 2014 Jun;99(6):956-64. doi: 10.3324/haematol.2013.085217.

39.

What lies beyond del(5q) in myelodysplastic syndrome?

Adema V, Bejar R.

Haematologica. 2013 Dec;98(12):1819-21. doi: 10.3324/haematol.2013.094912. No abstract available.

40.

Prognostic models in myelodysplastic syndromes.

Bejar R.

Hematology Am Soc Hematol Educ Program. 2013;2013:504-10. doi: 10.1182/asheducation-2013.1.504. Review.

PMID:
24319225
41.

The importance of subclonal genetic events in MDS.

Bejar R, Abdel-Wahab O.

Blood. 2013 Nov 21;122(22):3550-1. doi: 10.1182/blood-2013-09-527655.

42.

Toll-like receptor alterations in myelodysplastic syndrome.

Wei Y, Dimicoli S, Bueso-Ramos C, Chen R, Yang H, Neuberg D, Pierce S, Jia Y, Zheng H, Wang H, Wang X, Nguyen M, Wang SA, Ebert B, Bejar R, Levine R, Abdel-Wahab O, Kleppe M, Ganan-Gomez I, Kantarjian H, Garcia-Manero G.

Leukemia. 2013 Sep;27(9):1832-40. doi: 10.1038/leu.2013.180. Epub 2013 Jun 14.

43.

Myelodysplastic syndromes: recent advancements in risk stratification and unmet therapeutic challenges.

Bejar R, Tiu RV, Sekeres MA, Komrokji RS.

Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e256. Review.

44.

NRAS mutations with low allele burden have independent prognostic significance for patients with lower risk myelodysplastic syndromes.

Murphy DM, Bejar R, Stevenson K, Neuberg D, Shi Y, Cubrich C, Richardson K, Eastlake P, Garcia-Manero G, Kantarjian H, Ebert BL, Mike Makrigiorgos G.

Leukemia. 2013 Oct;27(10):2077-81. doi: 10.1038/leu.2013.160. Epub 2013 May 27. No abstract available.

45.

Semantics-driven modelling of user preferences for information retrieval in the biomedical domain.

Gladun A, Rogushina J, Valencia-García R, Béjar RM.

Inform Health Soc Care. 2013 Mar;38(2):150-70. doi: 10.3109/17538157.2012.735730. Epub 2013 Jan 16.

PMID:
23323596
46.

Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes.

Bejar R, Stevenson KE, Caughey BA, Abdel-Wahab O, Steensma DP, Galili N, Raza A, Kantarjian H, Levine RL, Neuberg D, Garcia-Manero G, Ebert BL.

J Clin Oncol. 2012 Sep 20;30(27):3376-82. doi: 10.1200/JCO.2011.40.7379. Epub 2012 Aug 6.

47.

Clinical effect of point mutations in myelodysplastic syndromes.

Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, Kantarjian H, Raza A, Levine RL, Neuberg D, Ebert BL.

N Engl J Med. 2011 Jun 30;364(26):2496-506. doi: 10.1056/NEJMoa1013343.

48.

Unraveling the molecular pathophysiology of myelodysplastic syndromes.

Bejar R, Levine R, Ebert BL.

J Clin Oncol. 2011 Feb 10;29(5):504-15. doi: 10.1200/JCO.2010.31.1175. Epub 2011 Jan 10. Review.

49.

The genetic basis of myelodysplastic syndromes.

Bejar R, Ebert BL.

Hematol Oncol Clin North Am. 2010 Apr;24(2):295-315. doi: 10.1016/j.hoc.2010.02.001. Review.

PMID:
20359627
50.

MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes.

Ikeda S, He A, Kong SW, Lu J, Bejar R, Bodyak N, Lee KH, Ma Q, Kang PM, Golub TR, Pu WT.

Mol Cell Biol. 2009 Apr;29(8):2193-204. doi: 10.1128/MCB.01222-08. Epub 2009 Feb 2.

Supplemental Content

Support Center